Previous 10 | Next 10 |
5 Active Programs With Near Term Catalysts. I/ONTEK Topline Data Release Expected As Early As April. Price Target of $10. For further details see: Citius: 2022 Is A Year Of Catalysts
CorMedix (NASDAQ:CRMD) is trading ~7% higher in the pre-market Monday after the development stage pharma company announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for DefenCath, an anti-infective solution. The regulators have determin...
BERKELEY HEIGHTS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the resubmission ...
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report it...
CorMedix (NASDAQ:CRMD) has appointed experienced pharmaceutical leader Joseph Todisco as CEO and a member of its Board of Directors. Mr. Todisco is expected to join CorMedix on May 16th or such earlier date as he completes his contractual responsibilities to his current employer. Previously, ...
BERKELEY HEIGHTS, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment of Jos...
Gainers: Mullen Automotive (NASDAQ:MULN) +126%. Renewable Energy Group (NASDAQ:REGI) +40%. IntriCon (NASDAQ:IIN) +37%. First Horizon (NYSE:FHN) +29%. Nordic American Tankers (NYSE:NAT) +27%. NeuroSense (NASDAQ:NRSN) +26%. CorMedix (NASDAQ:CRMD) +24%. Reata Pharmaceuticals (NASDAQ:RETA) +22%. ...
Gainers: IntriCon (NASDAQ:IIN) +37%. NeuroSense Therapeutics (NASDAQ:NRSN) +28%. Homology Medicines (NASDAQ:FIXX) +17%. CorMedix (NASDAQ:CRMD) +14%. Reata Pharmaceuticals (NASDAQ:RETA) +13%. Losers: Aurinia Pharmaceuticals (NASDAQ:AUPH) -29%. Lexicon Pharmac...
BERKELEY HEIGHTS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has resubmitted...
BERKELEY HEIGHTS, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix managemen...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...